25 February 2026 - The US FDA has approved Dupixent (dupilumab) for the treatment of adult and paediatric patients aged 6 years and older with allergic fungal rhinosinusitis with a history of sino-nasal surgery. 

This is the first approval for this condition.

Read FDA press release